Skip to content
KPRXKiora Pharmaceuticals Inc

Earnings

When Kiora Pharmaceuticals Inc reports, what it reported each quarter, and how the stock took the results.

51 quarters. Mar 31, 2014 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 24, before the open

Wed, Mar 24, 2027in 126 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 2 – 29

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$0.00
Revenue, change from a year earlier: Q3 2026 n/m, Q4 2025 n/m, Q3 2025 n/m, Q2 2025 −100.0%
Net income
-$6.52M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$1.00MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 12, 2026, before the openThe release
    Revenue
    $1.00M
    —
    Net income
    -$1.75M
    N/M
    EPS
    -$0.28
    N/M
    Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a business update highlighted by the in-licensing of KIO-401, a late-stage, oral neuroprotective calpain inhibitor.
  2. Q2 2026Aug 7, 2026, before the openThe release
    Revenue
    —
    —
    Net income
    -$2.08M
    N/M
    EPS
    -$0.34
    N/M
  3. Q1 2026May 8, 2026, before the openThe release0.0%by the close of May 8
    Revenue
    —
    —
    Net income
    -$2.42M
    N/M
    EPS
    -$0.58
    N/M
  4. Q4 2025Mar 25, 2026, before the openThe release6.0%by the close of Mar 26
    Revenue
    $0.00
    —
    Net income
    -$6.52M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · pre-marketNov 12, 202643 d10-Q$1.00M—-$0.28—
Q2 2026Jun 30, 2026Aug 7, 2026 · pre-marketAug 7, 202638 d10-Q——-$0.34—
Q1 2026Mar 31, 2026May 8, 2026 · pre-marketMay 8, 202638 d10-Q——-$0.580.0%
FY 2025
Q4 2025derivedDec 31, 2025Mar 25, 2026 · pre-marketMar 25, 202684 d10-K$0.00——6.0%
Q3 2025Sep 30, 2025Nov 7, 2025 · pre-marketNov 7, 202538 d10-Q$0.00—$0.016.5%
Q2 2025Jun 30, 2025Aug 8, 2025 · pre-marketAug 8, 202539 d10-Q$0.00−100.0%-$0.541.3%
Q1 2025Mar 31, 2025May 9, 2025 · pre-marketMay 9, 202539 d10-Q$0.00−100.0%-$0.523.9%
FY 2024
Q4 2024derivedDec 31, 2024Mar 25, 2025 · pre-marketMar 25, 202584 d10-K$0.00——7.0%
Q3 2024Sep 30, 2024Nov 8, 2024 · pre-marketNov 8, 202439 d10-Q$0.00—-$0.81+4.5%
Q2 2024Jun 30, 2024Aug 9, 2024 · pre-marketAug 9, 202440 d10-Q$20.00K—-$0.534.9%
Q1 2024Mar 31, 2024May 10, 2024 · pre-marketMay 10, 202440 d10-Q$16.00M—$3.46—
Earlier years, FY 2014 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026000092
10-QAug 7, 2026000074
10-QMay 8, 2026000047
10-KMar 25, 2026000024
10-QNov 7, 2025000078
10-QAug 8, 2025000061
10-QMay 9, 2025000044
10-KMar 25, 2025000012
10-QNov 8, 2024000120
10-QAug 9, 2024000104

Provenance

ProvenanceData status and checks

Kiora Pharmaceuticals Inc · CIK 1372514 · Engraved from SEC EDGAR